Hashimoto's Thyroiditis and Weight
Hashimoto's thyroiditis is the commonest cause of an underactive thyroid; the weight it adds is usually modest and largely fluid, and thyroid replacement restores health rather than producing weight loss.
Plain English
Patient-Friendly Explanation
Hashimoto's thyroiditis is an autoimmune condition in which the immune system gradually attacks the thyroid gland, the small butterfly-shaped gland in the neck that sets the pace of metabolism. It is named after the Japanese doctor who described it in 1912, and it is the commonest cause of an underactive thyroid where iodine intake is adequate. The hallmark is the presence of antibodies against thyroid peroxidase, found in about ninety-five per cent of people with the condition, and often against thyroglobulin as well. It is far more common in women and usually comes to light between the ages of thirty and fifty. The course is slow and silent. For years the thyroid function tests can be normal while the antibodies are present; a phase follows in which the thyroid-stimulating hormone is mildly raised while the free thyroid hormone is still normal, known as subclinical hypothyroidism; and in some people it progresses to overt hypothyroidism. Weight is one of the reasons people seek help, so it is worth being clear about what an underactive thyroid actually does. It lowers resting energy expenditure and causes a modest gain in weight, much of it fluid, often accompanied by fatigue, feeling cold, constipation, dry skin, hair thinning and heavier periods. What it does not do is cause large weight gain on its own, and treating it does not melt weight away. In one series of a hundred and one patients, the average change in weight after starting replacement was almost nothing, although about half of them lost some weight, on average just under four kilograms. A careful six-month study found that resting energy expenditure rose by around ten per cent on treatment, but the small change in weight came from lean tissue while fat mass stayed the same - and hunger increased. Two practical warnings follow. First, taking more thyroid hormone than the body needs in order to lose weight is ineffective and unsafe, because it strains the heart and thins the bones. Second, if the thyroid is underactive it should be treated properly, and the weight programme continues in parallel, because the two jobs are separate.
Medical
Clinical Definition
Hashimoto's thyroiditis, or chronic autoimmune (lymphocytic) thyroiditis, is an organ-specific autoimmune disease characterised by lymphocytic infiltration of the gland, follicular destruction and fibrosis, with circulating thyroid peroxidase antibodies in approximately 95 per cent of patients and thyroglobulin antibodies in 60 to 80 per cent. It is the commonest cause of hypothyroidism in iodine-sufficient regions, with an estimated prevalence now placed at 5 to 10 per cent, up from roughly 2 per cent a decade earlier, and a female-to-male ratio of about 4 to 10 to 1; NHANES III (n=17,353) found thyroid peroxidase antibody positivity in approximately 13 per cent of adults and overt hypothyroidism in about 4.6 per cent. Genetic susceptibility involves HLA-DR3 and DR4, CTLA-4, PTPN22 and CD25 variants, and the condition clusters with coeliac disease, type 1 diabetes and Addison's disease. Postpartum thyroiditis, regarded as a transient variant, affects 5 to 10 per cent of women in the first year after delivery, and 20 to 30 per cent of those affected develop permanent hypothyroidism within five years; antibody-positive subclinical hypothyroidism progresses to overt disease at roughly 4 to 5 per cent per year, about twice the rate seen in antibody-negative patients. Diagnosis rests on thyroid-stimulating hormone with free thyroxine and thyroid peroxidase antibodies, supported where needed by ultrasound showing hypoechogenicity; treatment is levothyroxine, typically around 1.6 micrograms per kilogram per day, titrated to the thyroid-stimulating hormone. The weight effects are smaller than commonly assumed. Overt hypothyroidism lowers resting energy expenditure and is associated with a modest gain in weight, predominantly fluid and fat, but full replacement does not reverse it in most patients: in a retrospective series of 101 newly diagnosed patients followed for up to 24 months, the median thyroid-stimulating hormone fell from 48 to 2.3 mIU/L while mean weight changed by only -0.1 kg overall, with 52 per cent losing weight and a mean loss of 3.8 kg among those who did. A prospective six-month study in 18 hypothyroid women recorded a 144 kcal/day (10 per cent) rise in resting energy expenditure, a mean weight change of only 1.1 kg composed of a reduction in fat-free mass with unchanged fat mass, and a significant increase in fasting hunger, which illustrates why restoration of thyroid status does not translate into fat loss. Overtreatment with levothyroxine does reduce weight but causes atrial fibrillation, accelerated bone loss and muscle wasting, and is not a legitimate weight-loss strategy. Selenium supplementation at 200 micrograms daily reduced antibody titres by 21 to 40 per cent over 12 months in two randomised trials without a consistent change in thyroid-stimulating hormone. Subclinical hypothyroidism is over-represented in obesity and a proportion of cases normalise with weight loss alone, so repeat testing after weight change is reasonable before committing to long-term replacement.
Key Insight
Why It Matters
A thyroid that is underactive should be treated properly, but patients should expect the tablets to restore energy, mood and metabolism rather than to shift the scales - and taking more of them than prescribed is harmful rather than helpful.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: October 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
